An observational study in Esophageal Neoplasms, Esophagectomy and Brain Metastases, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 8 sites in 6 countries. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Esophageal Neoplasms with a site in Netherlands — 30 open to participants now, 36 under way, 5 of them phase 3. Esophageal Neoplasms · Netherlands.
Among the 90 studies in Esophageal Neoplasms with a site in Netherlands, this one has the largest planned enrollment of the 25 observational ones that give a count, is one of 4 that started in 2020, is one of 25 observational ones, reaches primary completion later than 4 of the 35 other live ones, and was the 58th registered.
1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.
Browse Esophageal Neoplasms studies →30 of the 90 studies in Esophageal Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands, Norway, Spain
Ages 18+
Pfizer · Sites in Netherlands, United States, France and 3 more countries
Ages 18+
AstraZeneca · Sites in Netherlands, United States, Australia and 21 more countries
Ages 18+
Eli Lilly and Company · Sites in Netherlands, United States, China and 2 more countries
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 19 · Phase 3 8 · Phase 4 1
First in 2002; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 200 across 433 observational studies indexed under Esophageal Neoplasms.
Median enrollment 54 across the 65 interventional studies, 200 across the 25 observational. Of the 49 that completed or were terminated, 4 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 90 have an industry lead sponsor. The 10 most frequent:
Universitaire Ziekenhuizen KU Leuven is the lead sponsor of 965 studies on the registry; 268 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Universitaire Ziekenhuizen KU Leuven has 3 studies filed under Esophageal Neoplasms — fewer than ten, so there is no comparison to draw.
6 of the studies in Esophageal Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05188313Phase 3Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer | 2027-07 |
| NCT07114627Erasmus Medical CenterImpact of CES1 Genotype on Capecitabine Exposure in Cancer Patients | 2026-12 |
| NCT06687876Amsterdam UMC, location VUmcMetformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy | 2026-12 |
| NCT04379596AstraZenecaPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | 2027-05-04 |
| NCT07108855University Medical Center GroningenDetection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic Administration of Indocyanine Green During Endoscopic Submucosal Dissection | 2027-06-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 90 studies in Esophageal Neoplasms with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Esophagectomy is the cornerstone of the curative treatment of esophageal carcinoma. Despite this treatment, patients can suffer from locoregional or distant metastatic disease and only a very selected group of patients can be cured: mostly those with recurrence in one single organ.
Brain metastases are rare after esophagectomy for cancer, but they have a serious impact on survival. Agressive treatment is often moren difficult for brain metastases compared to other metastases and some risk factors have been identified earlier.
There is an impression that the incidence of brain metastases in esophageal cancer patients has increased since the introduction of neoadjuvant treatment schemes. However, this is not clear yet. A potential explanation could be that chemotherapy disturbs the blood-brain-barrier, hereby facilitating the migration of tumor cells to the brain.
The purpose of this study is to retrospectively analyze the incidence and potential risk factors of brain metastases in patients who underwent esophagectomy for esophageal cancer. Patients treated between 2000 and 2019 will be included and outcome parameters are Odds Ratio for brain metastases (comparison between primary surgery and neoadjuvant treatment followed by surgery), time to recurrence and risk factors, number and characteristics of the brain metastases.
Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Surgical removal of (a part of) the esophagus and surgical reconstruction with another organ (mostly stomach, but may be colon or small bowel as well)
Odds ratio (OR) for brain metastasis
Odds ratio (OR) for brain metastasis compared between primary surgery and neoadjuvant treatment plus surgery, OR for different neoadjuvant treatment regimes, corrected for gender and tumor factors (histology, stage, tumor differentiation,...) .
Time frame: 1 January 2000 - 1 March 2020
Overall survival
Overall survival after diagnosis of brain metastases stratified for treatment regimens applied.
Time frame: 1 January 2000 - 1 March 2020
Time to recurrence
Time to recurrence, between incidence date of esophageal cancer and diagnosis of brainM+
Time frame: 1 January 2000 - 1 March 2020
Risk factors for single site brain metastasis
such as different neoadjuvant treatment regimes, age, gender,and tumor factors (histology, stage, tumor differentiation,...)
Time frame: 1 January 2000 - 1 March 2020
Number of brain metastases
Number of brain metastases
Time frame: 1 January 2000 - 1 March 2020
Characteristics of brain metastases
solitary/multiple; location /side in the brain; treatment) and the effects on 'OS after recurrence' (e.g. is there a significant survival benefit in patients with brainM+ if they are treated with brain-surgery and/or stereotactic radiotherapy compared to non-treated BrainM+ or palliative treatments of brainM+
Time frame: 1 January 2000 - 1 March 2020
Started Jun 2020 (actual). Primary completion is estimated for Mar 2025, 57 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitaire Ziekenhuizen KU Leuven →